Lenvatinib (Kisplyx®) is accepted for use within NHS Scotland
Scottish Medicines Consortium - SMC
Scottish Medicines Consortium
11 November 2019
Lenvatinib is approved for use in NHS Scotland, in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF)-targeted therapy.